Evidence map›Paper›PMID 23470147›Full record

ArticleBiochemistry2013

A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Ali Emileh, Ferit Tuzer, Herman Yeh, Muddegowda Umashankara, Diogo R M Moreira, Judith M Lalonde, Carole A Bewley, Cameron F Abrams, Irwin M Chaiken

Abstract read
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Nanoparticles in clinical trials of COVID-19: An update.International journal of surgery (London, England) · 2022
    Review
  4. Article
  5. Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021
    Review
  6. 1,2,3-Triazoles as Biomimetics in Peptide Science.Molecules (Basel, Switzerland) · 2021
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ali EmilehChemical and Biological Engineering, Drexel University, Philadelphia, PA 19104, USA. ali.emileh@drexel.edu
Ferit Tuzer
Herman Yeh
Muddegowda Umashankara
Diogo R M Moreira
Judith M Lalonde
Carole A Bewley
Cameron F Abrams
Irwin M Chaiken
Drexel University · USNational Institutes of Health · USBryn Mawr College · US

Funding

Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
Inhibitors and Probes of HIV-1 Cell FusionZIADK032103 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI BEWLEY, CAROLE · 2009 to 2025
$12.5M
Epitope-Focused HIV-1 Envelope Vaccine for HIV-1/AIDSR21AI091513 · NIAID · DREXEL UNIVERSITY · PI CHAIKEN, IRWIN M · 2010 to 2011
$441k
HIV-1 gp120 Conformational Transitions in Activation and AntagonismR21AI093248 · NIAID · DREXEL UNIVERSITY · PI ABRAMS, CAMERON F, CHAIKEN, IRWIN M · 2011 to 2012
$428k
Intramural NIH HHS ZIA DK032103NIAID NIH HHS 5R21AI091513-02NIAID NIH HHS 5R21AI093248-02NIAID NIH HHS R21 AI091513NIAID NIH HHS R21 AI093248NIGMS NIH HHS 5P01GM056550NIGMS NIH HHS P01 GM056550
6 · The paper itself

Abstract

Peptide triazole (PT) entry inhibitors prevent HIV-1 infection by blocking the binding of viral gp120 to both the HIV-1 receptor and the coreceptor on target cells. Here, we used all-atom explicit solvent molecular dynamics (MD) to propose a model for the encounter complex of the peptide triazoles with gp120. Saturation transfer difference nuclear magnetic resonance (STD NMR) and single-site mutagenesis experiments were performed to test the simulation results. We found that docking of the peptide to a conserved patch of residues lining the "F43 pocket" of gp120 in a bridging sheet naïve gp120 conformation of the glycoprotein led to a stable complex. This pose prevents formation of the bridging sheet minidomain, which is required for receptor-coreceptor binding, providing a mechanistic basis for dual-site antagonism of this class of inhibitors. Burial of the peptide triazole at the gp120 inner domain-outer domain interface significantly contributed to complex stability and rationalizes the significant contribution of hydrophobic triazole groups to peptide potency. Both the simulation model and STD NMR experiments suggest that the I-X-W [where X is (2S,4S)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine] tripartite hydrophobic motif in the peptide is the major contributor of contacts at the gp120-PT interface. Because the model predicts that the peptide Trp side chain hydrogen bonding with gp120 S375 contributes to the stability of the PT-gp120 complex, we tested this prediction through analysis of peptide binding to gp120 mutant S375A. The results showed that a peptide triazole KR21 inhibits S375A with 20-fold less potency than WT, consistent with predictions of the model. Overall, the PT-gp120 model provides a starting point for both the rational design of higher-affinity peptide triazoles and the development of structure-minimized entry inhibitors that can trap gp120 into an inactive conformation and prevent infection.

Indexed as

Anti-HIV AgentsHIV-1HIV Envelope Protein gp120HIV InfectionsHumansMolecular Docking SimulationMolecular Dynamics SimulationMutagenesis, Site-DirectedNuclear Magnetic Resonance, BiomolecularPeptidesProtein ConformationTriazolesAnti-HIV AgentsHIV Envelope Protein gp120PeptidesTriazoles

Identifiers

PMID23470147
PMCPMC3800186
OpenAlexW1998336888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.